Moberg Pharma: APAC expansion further de-risks commercial path - Redeye

Moberg Pharma and Karo Healthcare have announced an expansion of their licensing agreement for MOB-015 (Terclara®), now including Australia, New Zealand, South Korea, and Taiwan. By leveraging Karo’s established infrastructure in these regions, Moberg secures a high-authority entry point into markets with a total population of 100m people, further de-risking the global roll-out.

Länk till analysen i sin helhet: https://www.redeye.se/research/1161696/moberg-pharma-apac-expansion-further-de-risks-commercial-path?utm_source=finwire&utm_medium=RSS